IBDEI3GR ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,58258,2)
;;=^5002641
;;^UTILITY(U,$J,358.3,58259,0)
;;=E11.351^^272^2905^21
;;^UTILITY(U,$J,358.3,58259,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58259,1,3,0)
;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58259,1,4,0)
;;=4^E11.351
;;^UTILITY(U,$J,358.3,58259,2)
;;=^5002640
;;^UTILITY(U,$J,358.3,58260,0)
;;=E11.349^^272^2905^22
;;^UTILITY(U,$J,358.3,58260,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58260,1,3,0)
;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/o Macular Edema
;;^UTILITY(U,$J,358.3,58260,1,4,0)
;;=4^E11.349
;;^UTILITY(U,$J,358.3,58260,2)
;;=^5002639
;;^UTILITY(U,$J,358.3,58261,0)
;;=E11.341^^272^2905^23
;;^UTILITY(U,$J,358.3,58261,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58261,1,3,0)
;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58261,1,4,0)
;;=4^E11.341
;;^UTILITY(U,$J,358.3,58261,2)
;;=^5002638
;;^UTILITY(U,$J,358.3,58262,0)
;;=E11.339^^272^2905^18
;;^UTILITY(U,$J,358.3,58262,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58262,1,3,0)
;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/o Macular Edema
;;^UTILITY(U,$J,358.3,58262,1,4,0)
;;=4^E11.339
;;^UTILITY(U,$J,358.3,58262,2)
;;=^5002637
;;^UTILITY(U,$J,358.3,58263,0)
;;=E11.331^^272^2905^19
;;^UTILITY(U,$J,358.3,58263,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58263,1,3,0)
;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58263,1,4,0)
;;=4^E11.331
;;^UTILITY(U,$J,358.3,58263,2)
;;=^5002636
;;^UTILITY(U,$J,358.3,58264,0)
;;=E11.329^^272^2905^16
;;^UTILITY(U,$J,358.3,58264,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58264,1,3,0)
;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/o Macular Edema
;;^UTILITY(U,$J,358.3,58264,1,4,0)
;;=4^E11.329
;;^UTILITY(U,$J,358.3,58264,2)
;;=^5002635
;;^UTILITY(U,$J,358.3,58265,0)
;;=E11.321^^272^2905^17
;;^UTILITY(U,$J,358.3,58265,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58265,1,3,0)
;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58265,1,4,0)
;;=4^E11.321
;;^UTILITY(U,$J,358.3,58265,2)
;;=^5002634
;;^UTILITY(U,$J,358.3,58266,0)
;;=E11.319^^272^2905^24
;;^UTILITY(U,$J,358.3,58266,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58266,1,3,0)
;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/o Macular Edema
;;^UTILITY(U,$J,358.3,58266,1,4,0)
;;=4^E11.319
;;^UTILITY(U,$J,358.3,58266,2)
;;=^5002633
;;^UTILITY(U,$J,358.3,58267,0)
;;=E11.311^^272^2905^25
;;^UTILITY(U,$J,358.3,58267,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58267,1,3,0)
;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58267,1,4,0)
;;=4^E11.311
;;^UTILITY(U,$J,358.3,58267,2)
;;=^5002632
;;^UTILITY(U,$J,358.3,58268,0)
;;=E10.9^^272^2905^13
;;^UTILITY(U,$J,358.3,58268,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58268,1,3,0)
;;=3^DM Type 1 w/o Complications
;;^UTILITY(U,$J,358.3,58268,1,4,0)
;;=4^E10.9
;;^UTILITY(U,$J,358.3,58268,2)
;;=^5002626
;;^UTILITY(U,$J,358.3,58269,0)
;;=E10.311^^272^2905^11
;;^UTILITY(U,$J,358.3,58269,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58269,1,3,0)
;;=3^DM Type 1 w/ Unspec Diab Retinopathy w/ Macular Edema
;;^UTILITY(U,$J,358.3,58269,1,4,0)
;;=4^E10.311
;;^UTILITY(U,$J,358.3,58269,2)
;;=^5002592
;;^UTILITY(U,$J,358.3,58270,0)
;;=E10.319^^272^2905^12
;;^UTILITY(U,$J,358.3,58270,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,58270,1,3,0)
;;=3^DM Type 1 w/ Unspec Diab Retinopathy w/o Macular Edema
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3GR 3958 printed Nov 22, 2024@17:58:36 Page 2
IBDEI3GR ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,58258,2)
+2 ;;=^5002641
+3 ;;^UTILITY(U,$J,358.3,58259,0)
+4 ;;=E11.351^^272^2905^21
+5 ;;^UTILITY(U,$J,358.3,58259,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,58259,1,3,0)
+8 ;;=3^DM Type 2 w/ Prolif Diab Retinopathy w/ Macular Edema
+9 ;;^UTILITY(U,$J,358.3,58259,1,4,0)
+10 ;;=4^E11.351
+11 ;;^UTILITY(U,$J,358.3,58259,2)
+12 ;;=^5002640
+13 ;;^UTILITY(U,$J,358.3,58260,0)
+14 ;;=E11.349^^272^2905^22
+15 ;;^UTILITY(U,$J,358.3,58260,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,58260,1,3,0)
+18 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/o Macular Edema
+19 ;;^UTILITY(U,$J,358.3,58260,1,4,0)
+20 ;;=4^E11.349
+21 ;;^UTILITY(U,$J,358.3,58260,2)
+22 ;;=^5002639
+23 ;;^UTILITY(U,$J,358.3,58261,0)
+24 ;;=E11.341^^272^2905^23
+25 ;;^UTILITY(U,$J,358.3,58261,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,58261,1,3,0)
+28 ;;=3^DM Type 2 w/ Severe NonProlif Diab Retinopathy w/ Macular Edema
+29 ;;^UTILITY(U,$J,358.3,58261,1,4,0)
+30 ;;=4^E11.341
+31 ;;^UTILITY(U,$J,358.3,58261,2)
+32 ;;=^5002638
+33 ;;^UTILITY(U,$J,358.3,58262,0)
+34 ;;=E11.339^^272^2905^18
+35 ;;^UTILITY(U,$J,358.3,58262,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,58262,1,3,0)
+38 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/o Macular Edema
+39 ;;^UTILITY(U,$J,358.3,58262,1,4,0)
+40 ;;=4^E11.339
+41 ;;^UTILITY(U,$J,358.3,58262,2)
+42 ;;=^5002637
+43 ;;^UTILITY(U,$J,358.3,58263,0)
+44 ;;=E11.331^^272^2905^19
+45 ;;^UTILITY(U,$J,358.3,58263,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,58263,1,3,0)
+48 ;;=3^DM Type 2 w/ Moderate NonProlif Diab Retinopathy w/ Macular Edema
+49 ;;^UTILITY(U,$J,358.3,58263,1,4,0)
+50 ;;=4^E11.331
+51 ;;^UTILITY(U,$J,358.3,58263,2)
+52 ;;=^5002636
+53 ;;^UTILITY(U,$J,358.3,58264,0)
+54 ;;=E11.329^^272^2905^16
+55 ;;^UTILITY(U,$J,358.3,58264,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,58264,1,3,0)
+58 ;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/o Macular Edema
+59 ;;^UTILITY(U,$J,358.3,58264,1,4,0)
+60 ;;=4^E11.329
+61 ;;^UTILITY(U,$J,358.3,58264,2)
+62 ;;=^5002635
+63 ;;^UTILITY(U,$J,358.3,58265,0)
+64 ;;=E11.321^^272^2905^17
+65 ;;^UTILITY(U,$J,358.3,58265,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,58265,1,3,0)
+68 ;;=3^DM Type 2 w/ Mild NonProlif Diab Retinopathy w/ Macular Edema
+69 ;;^UTILITY(U,$J,358.3,58265,1,4,0)
+70 ;;=4^E11.321
+71 ;;^UTILITY(U,$J,358.3,58265,2)
+72 ;;=^5002634
+73 ;;^UTILITY(U,$J,358.3,58266,0)
+74 ;;=E11.319^^272^2905^24
+75 ;;^UTILITY(U,$J,358.3,58266,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,58266,1,3,0)
+78 ;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/o Macular Edema
+79 ;;^UTILITY(U,$J,358.3,58266,1,4,0)
+80 ;;=4^E11.319
+81 ;;^UTILITY(U,$J,358.3,58266,2)
+82 ;;=^5002633
+83 ;;^UTILITY(U,$J,358.3,58267,0)
+84 ;;=E11.311^^272^2905^25
+85 ;;^UTILITY(U,$J,358.3,58267,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,58267,1,3,0)
+88 ;;=3^DM Type 2 w/ Unspec Diab Retinopathy w/ Macular Edema
+89 ;;^UTILITY(U,$J,358.3,58267,1,4,0)
+90 ;;=4^E11.311
+91 ;;^UTILITY(U,$J,358.3,58267,2)
+92 ;;=^5002632
+93 ;;^UTILITY(U,$J,358.3,58268,0)
+94 ;;=E10.9^^272^2905^13
+95 ;;^UTILITY(U,$J,358.3,58268,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,58268,1,3,0)
+98 ;;=3^DM Type 1 w/o Complications
+99 ;;^UTILITY(U,$J,358.3,58268,1,4,0)
+100 ;;=4^E10.9
+101 ;;^UTILITY(U,$J,358.3,58268,2)
+102 ;;=^5002626
+103 ;;^UTILITY(U,$J,358.3,58269,0)
+104 ;;=E10.311^^272^2905^11
+105 ;;^UTILITY(U,$J,358.3,58269,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,58269,1,3,0)
+108 ;;=3^DM Type 1 w/ Unspec Diab Retinopathy w/ Macular Edema
+109 ;;^UTILITY(U,$J,358.3,58269,1,4,0)
+110 ;;=4^E10.311
+111 ;;^UTILITY(U,$J,358.3,58269,2)
+112 ;;=^5002592
+113 ;;^UTILITY(U,$J,358.3,58270,0)
+114 ;;=E10.319^^272^2905^12
+115 ;;^UTILITY(U,$J,358.3,58270,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,58270,1,3,0)
+118 ;;=3^DM Type 1 w/ Unspec Diab Retinopathy w/o Macular Edema
